Related Experiment Videos
Serum free light chains: diagnostic and prognostic value in multiple myeloma
Pavai Sthaneshwar1, Veerasekaran Nadarajan, Jayaranee A S Maniam
1Department of Pathology, University of Malaya, Kuala Lumpur, Malaya. pavai@um.edu.my
Clinical Chemistry and Laboratory Medicine
|September 5, 2009
Summary
The serum free light chain (FLC) assay improves multiple myeloma (MM) diagnosis sensitivity when combined with serum protein electrophoresis. An abnormal kappa/lambda FLC ratio at baseline indicates poorer survival in MM patients.
Area of Science:
- Clinical Chemistry
- Hematology
- Oncology
Background:
- Serum free light chains (FLCs) measurement is a new tool for diagnosing and monitoring plasma cell dyscrasias.
- The study investigates the utility of serum FLC assay as a tumor marker for multiple myeloma (MM).
Purpose of the Study:
- To compare the diagnostic performance of serum FLC assay with serum protein electrophoresis (PE) for MM.
- To evaluate the prognostic value of the baseline serum FLC ratio in MM patients.
Main Methods:
- Measured FLC concentrations and calculated kappa/lambda (kappa/lambda) FLC ratios in control, polyclonal gammopathy, and MM groups.
- Assessed diagnostic sensitivity and specificity using a cut-off threshold of 2.0 for the FLC ratio.
Main Results:
- The FLC ratio demonstrated higher sensitivity and specificity than serum electrophoresis for MM diagnosis.
- Abnormal baseline serum FLC ratios (kappa/lambda >57.5 or <0.04) were associated with significantly poorer survival (30 months vs. 47 months, p<0.011).
Conclusions:
- Serum FLC assay, combined with serum PE, enhances diagnostic sensitivity for MM.
- Baseline kappa/lambda FLC ratio measurement provides valuable prognostic information for MM patients.
